Janssen updates manufacturing software systems at Belgium API plant

By Dan Stanton contact

- Last updated on GMT

Janssen's Geel, Belgium API plant has updated its manufacturing execution software
Janssen's Geel, Belgium API plant has updated its manufacturing execution software

Related tags: Pharmacology, Manufacturing, Pharmaceutical drug

Johnson & Johnson has updated its manufacturing execution software (MES) at an active pharmaceutical ingredient (API) in Belgium.

J&J’s pharmaceutical subsidiary Janssen has been using the PAS-X software, supplied by Germany-based firm Werum IT Solutions, at its API facility in Geel, Belgium for a number of years in order to manage its manufacturing operations including managing process quality control, material flow and master batch records.

300 members of its workforce have access to the software and Janssen has now updated Werum’s MES solution to the latest version.

“After operating the previous version for about two years, we have updated the PAS-X system in Geel in order to benefit from the improved out-of-the-box product functionality,”​ Anje Vermeiren, Senior Manager Manufacturing Systems of J&J said. These include “enhanced Master Batch Record functions, easier ways of reviewing Electronic Batch Records and enriched handheld functionality.”

According to Werum, paper-based documentation is still fairly common in pharma plants despite such operations tending to be unstructured and inefficient. The firm’s MES offers configurable electronic approval and release workflows offering, and brings benefits to companies, for example detecting deviations early in quality assurance.

Janssen’s site in Geel has a workforce of 760 and produces 70 different active substances for about two-thirds of J&J’s medicines portfolio.

Earlier this year​, J&J announced it was investing almost €60m ($75m) to renovate the site. “Geel is by far the largest manufacturer of our raw materials for small molecules and is a key player within the whole of the Janssen Supply Chain,”​ CEO of Janssen Belgium Tom Heyman said at the time, according to Janssen's website​.

Peter Putteman, General Manager of Chemical Production Belgium, added: “This renovation allows the high-tech production unit to continue to fulfil its important role in the manufacture of medicines which meet major medical needs on a global scale.”

Related news

Show more

Related products

show more

ODM and CDASH in CRF design

ODM and CDASH in CRF design

Formedix | 15-Aug-2022 | Technical / White Paper

The lesser-known Operational Data Model (ODM) standard is often overlooked as it's not required by any regulators. So, why should you be interested...

Standardizing data with NCI controlled terminology

Standardizing data with NCI controlled terminology

Formedix | 18-Jul-2022 | Technical / White Paper

The use of consistent terminology within and between studies is critical to enabling an efficient trial process. CDISC standards such as CDASH, SDTM, SEND...

How clinical trial software can optimize trials

How clinical trial software can optimize trials

Formedix | 20-Jun-2022 | Technical / White Paper

This article explains the different types of clinical trial software available, and how it can be used to optimize the end to end clinical trials design...

Governing and Maintaining Clinical Data Standards

Governing and Maintaining Clinical Data Standards

Veeva | 10-May-2022 | Technical / White Paper

Investing in data standards plays a huge role in improving the quality of clinical studies. But often, people don’t use the standards correctly, there...

Related suppliers

Follow us

Products

View more

Webinars